Skip to main content
Premium Trial:

Request an Annual Quote

Precision Bio, Nova Synthetix to Collaborate on Ricin-Free Castor Plant Development

NEW YORK (GenomeWeb News) – Precision BioSciences and Nova Synthetix today announced a deal for the use of each other's technologies to generate "non-GM," ricin-free castor plants.

Precision Bio's Directed Nuclease Editor gene editing technology and Nova's proprietary plant transformation system will be used in work covered by the agreement. The DNE technology produces genome-editing enzymes that can "insert, remove, modify, and regulate essentially any gene in mammalian or plant cells," the firms noted in a statement.

The companies also plan to generate improved castor variants "capable of producing user-defined oil profiles for industrial, biofuel, and feed-directed applications," they said. The effort is anticipated to produce a castor plant that is safer and has greater market use.

Financial and other terms were not disclosed.

"This effort presents the opportunity to combine both companies' [technologies] to create crop varieties with superior genetics for all sorts of industrial and food applications," said Nova President Don Walters.

Earlier in the week Precision Bio announced a deal with Agrivida for use of the Directed Nuclease Editor technology aimed at corn.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.